The ostensible 'flexibilities' in TRIPS: can essential pharmaceuticals be excluded from patentability in public health crises?

    Research output: Contribution to journalArticleResearchpeer-review

    Original languageEnglish
    Pages (from-to)335 - 356
    Number of pages22
    JournalMonash University Law Review
    Volume32
    Issue number2
    Publication statusPublished - 2006

    Cite this